COVID-19: Salvage TOcilizumab as a Rescue Measure

Inclusion Criteria: * written informed consaent obtained * hospitalized with COVID-19 disease * Age \>/= 18 years * SARS CoV-2 NhO posit * Sp=2 \</93% on ambient air or respiratory rate \>30 /min * Any 2 of the 4: P-IL-6 \> 2 x ULN / P-ferritin \> 2 x ULN / P-FIDD \>1.5 mg/l / P- CRP \>40 mg/l without obvious presence of bacterial infection (normal values: P -IL-6 \<5.9 ng/l; P-ferritin, men 30-400 mikrog/l, women 13-150 mikrog/l ; P-FIDD (Fibrin degradation products, D-dimer) \<0.5 mg/l; P-CRP \<10 mg/l) Exclusion Criteria: * Known severe allergic reactions to monoclonal antibodies * Active confirmed tuberculosis with ongoing treatment or obvious tuberculosis or obvious other bacterial, fungal or viral infection (besides COVID-19) * In the opinion of the clinical team, progression to death is imminent and inevitable within the next 24 hours, irrespective of the provision of treatments * Long-term oral anti-rejection or immunomodulatory drugs (including corticosteroids equivalent to methylprednison 15mg/day) * Pregnant or lactating women. If needed, exclusion of pregnancy should be performed by laboratory test (U-hCG-O). * Participating in other drug clinical trials * Absolute neutrophil count \< 1 x10E9/l * Platelet count \<50 x10E9/l * ALAT \>10x ULN